Agendia, Agilent expand breast cancer pact
This article was originally published in Clinica
Dutch gene expression specialist Agendia is set to work more closely with its assay component supplier Agilent Technologies in a bid to develop new in vitro diagnostic tests for cancer. The deal, of which financial details were not disclosed, will see Santa Clara, California-based Agilent work with Agendia on the R&D and commercialisation of the new cancer test, as opposed to just being a supplier. Agendia and Agilent will provide each other with access to information about their research into genetic biomarkers.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.